Autolus Therapeutics AUTL 深 滬
等待開盤 10-08 09:30:00 美东时间
1.81
+0.020
+1.12%
華盛通- 最 高1.81
- 今 開1.78
- 成交量 155.02万股
- 最 低 1.73
- 昨 收 1.79
- 總市值 4.82亿
- 52周最高 2.58
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.175
- 委 比 59.21%
- 總股本 2.66亿
- 歷史最高 53.24
- 量 比 0.90
- 振 幅 4.47%
- 歷史最低 1.105
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Con...
10-05 20:34
The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026. LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory LN, continues enrolling i...
09-09 19:09
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Autolus Therapeutics' obe-cel has received FDA's RMAT designation for treating SLE and LN, aiming to accelerate its development. The Phase 2 LUMINA trial for refractory LN is ongoing in five countries, with data expected in 2028. Dr. Matthias Will highlighted the significance of this designation in addressing unmet needs for severe autoimmune diseases.
09-09 11:00
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
08-12 00:57
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported Q2 2026 net product revenue of $45.7 million for AUCATZYL®, up 119% YoY, with FY 2026 guidance raised to $140-$150 million. Gross margin improved due to higher volumes and cost reduction initiatives. The company secured a $250 million credit facility, with $75 million funded. Obe-cel clinical trials are progressing in lupus nephritis, pediatric ALL, and progressive MS. CEO Dr. Christian Itin highlighted strong adopti...
08-11 11:00
Autolus Therapeutics Q2 2026 Earnings Preview
Autolus Therapeutics (AUTL) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. The consensus EPS Estimate is -$0.19 (-5.6% Y/Y) and the consensus Revenue Estimat...
08-10 23:00
美股牛股 | Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股
Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股；AAOI升逾16%，英伟达官宣CPO步入量产提振板块>>
08-04 19:06
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.
08-03 20:52
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 million Capital base strengthened through five-year, interest-only credit facilit...
08-03 19:20
